Literature DB >> 11602621

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

S Eddahibi1, M Humbert, E Fadel, B Raffestin, M Darmon, F Capron, G Simonneau, P Dartevelle, M Hamon, S Adnot.   

Abstract

Hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is a hallmark pathological feature of primary pulmonary hypertension (PPH). Here we found that PA-SMCs from patients with PPH grow faster than PA-SMCs from controls when stimulated by serotonin or serum and that these effects are due to increased expression of the serotonin transporter (5-HTT), which mediates internalization of indoleamine. In the presence of 5-HTT inhibitors, the growth stimulatory effects of serum and serotonin were markedly reduced and the difference between growth of PA-SMCs from patients and controls was no longer observed. As compared with controls, the expression of 5-HTT was increased in cultured PA-SMCs as well as in platelets and lungs from patients with PPH where it predominated in the media of thickened pulmonary arteries and in onion-bulb lesions. The L-allelic variant of the 5HTT gene promoter, which is associated with 5-HTT overexpression and increased PA-SMC growth, was present in homozygous form in 65% of patients but in only 27% of controls. We conclude that 5-HTT activity plays a key role in the pathogenesis of PA-SMC proliferation in PPH and that a 5HTT polymorphism confers susceptibility to PPH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602621      PMCID: PMC209526          DOI: 10.1172/JCI12805

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Competitive PCR.

Authors:  P D Siebert; J W Larrick
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

2.  Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.

Authors:  R B Rothman; M A Ayestas; C M Dersch; M H Baumann
Journal:  Circulation       Date:  1999-08-24       Impact factor: 29.690

3.  [Are the primary vascular forms of chronic pulmonary heart disease becoming more common?].

Authors:  H P Gurtner; M Gertsch; C Salzmann; M Scherrer; P Stucki; F Wyss
Journal:  Schweiz Med Wochenschr       Date:  1968-10-12

4.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

5.  Reduced serotonin uptake by spontaneously hypertensive rat platelets.

Authors:  R Prina; E Dolfini; T Mennini; A Palermo; A Libretti
Journal:  Life Sci       Date:  1981-12-07       Impact factor: 5.037

6.  Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats.

Authors:  S Eddahibi; S Adnot; E Frisdal; M Levame; M Hamon; B Raffestin
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

7.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

8.  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

Authors:  S Eddahibi; N Hanoun; L Lanfumey; K P Lesch; B Raffestin; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

9.  Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior.

Authors:  P Gorwood; P Batel; J Adès; M Hamon; C Boni
Journal:  Biol Psychiatry       Date:  2000-08-15       Impact factor: 13.382

10.  Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior.

Authors:  T Hallikainen; T Saito; H M Lachman; J Volavka; T Pohjalainen; O P Ryynänen; J Kauhanen; E Syvälahti; J Hietala; J Tiihonen
Journal:  Mol Psychiatry       Date:  1999-07       Impact factor: 15.992

View more
  120 in total

Review 1.  Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension.

Authors:  M Rabinovitch
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 2.  Pulmonary hypertension in the young.

Authors:  Sheila G Haworth
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

3.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

Review 4.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

5.  Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells.

Authors:  Wenying Ren; Stephanie W Watts; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-24       Impact factor: 5.464

6.  Lessons learned from cancer may help in the treatment of pulmonary hypertension.

Authors:  Serge Adnot
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 7.  One hundred years of research in the pathogenesis of pulmonary hypertension.

Authors:  Ari Zaiman; Iwona Fijalkowska; Paul M Hassoun; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

Review 8.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

9.  Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.

Authors:  Christopher C Sullivan; Lingling Du; Danny Chu; Augustine J Cho; Masakuni Kido; Paul L Wolf; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

10.  Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.